Literature DB >> 10050719

Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma.

H I Sati1, M Greaves, J F Apperley, R G Russell, P I Croucher.   

Abstract

Interleukin-1beta(IL-1beta) and tumour necrosis factor-alpha (TNF-alpha) are potent bone resorbing cytokines that may contribute to the development of the osteolytic bone disease observed in patients with multiple myeloma (MM). Although these factors have been identified in cultures of bone marrow mononuclear cells isolated from patients, the identity of the cells responsible for producing IL-1beta and TNFalpha remains unclear. Using a sensitive dual-colour fluorescence in situ hybridization (FISH) technique and a two-colour immunofluorescence method we have investigated the expression of the mRNA and protein, for IL-1beta and TNFalpha, by individual bone marrow plasma cells from patients with MM and monoclonal gammopathy of undetermined significance (MGUS). The mRNA for IL-1beta and TNFalpha was identified in all cells expressing the immunoglobulin light chain from all patients with MM and MGUS. However, the IL-1beta protein could not be detected in cytoplasmic light chain positive cells in any of the patients examined. In contrast, the TNFalpha protein was detected in clonal plasma cells from patients with both MM and MGUS. Interestingly, the IL-1beta and TNFalpha mRNA and proteins were readily detected within a small proportion of the non-plasma cells from patients with both MM and MGUS. These data suggest that myeloma cells in vivo are able to produce TNFalpha but not IL-1beta. In addition, a small proportion of accessory cells are likely to be able to contribute to the production of both ILbeta and TNFalpha.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10050719     DOI: 10.1046/j.1365-2141.1999.01193.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Pasteurella multocida toxin-stimulated osteoclast differentiation is B cell dependent.

Authors:  Dagmar Hildebrand; Klaus Heeg; Katharina F Kubatzky
Journal:  Infect Immun       Date:  2010-10-18       Impact factor: 3.441

2.  Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages.

Authors:  Omar A Al Obeed; Khayal A Alkhayal; Abdulmalik Al Sheikh; Ahmad M Zubaidi; Mansoor-Ali Vaali-Mohammed; Robin Boushey; James H Mckerrow; Maha-Hamadien Abdulla
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

3.  Tumor necrosis factor-α is associated with positive lymph node status in patients with recurrence of colorectal cancer-indications for anti-TNF-α agents in cancer treatment.

Authors:  M Grimm; M Lazariotou; S Kircher; A Höfelmayr; C T Germer; B H A von Rahden; A M Waaga-Gasser; M Gasser
Journal:  Cell Oncol (Dordr)       Date:  2011-08       Impact factor: 6.730

Review 4.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

5.  First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.

Authors:  Thomas Lund; Kent Søe; Niels Abildgaard; Patrick Garnero; Per T Pedersen; Tina Ormstrup; Jean-Marie Delaissé; Torben Plesner
Journal:  Eur J Haematol       Date:  2010-07-22       Impact factor: 2.997

6.  Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma.

Authors:  Wenjie He; Amitabha Mazumder; Tuere Wilder; Bruce N Cronstein
Journal:  FASEB J       Date:  2013-05-16       Impact factor: 5.191

7.  Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells.

Authors:  Ulrike Heider; Ivana Zavrski; Christian Jakob; Katharina Bängeroth; Claudia Fleissner; Corinna Langelotz; Kurt Possinger; Lorenz C Hofbauer; Volker Viereck; Orhan Sezer
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

8.  Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.

Authors:  Barbara Zdzisińska; Agnieszka Bojarska-Junak; Anna Dmoszyńska; Martyna Kandefer-Szerszeń
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-05-30       Impact factor: 4.291

9.  Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.

Authors:  Irfan Kuku; Mehmet Refik Bayraktar; Emin Kaya; Mehmet Ali Erkurt; Nihayet Bayraktar; Kerim Cikim; Ismet Aydogdu
Journal:  Mediators Inflamm       Date:  2005-08-14       Impact factor: 4.711

10.  Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.

Authors:  Jingnan Sun; Xue Wen; Fengyan Jin; Yuying Li; Jifan Hu; Yunpeng Sun
Journal:  Onco Targets Ther       Date:  2015-09-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.